Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS)

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

A Bayesian latent-subgroup platform design for dose optimization

Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials

Shotgun: A Bayesian Seamless Phase I-II Design to Accelerate the Development of Targeted Therapies and Immunotherapy.

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials

Multiplicity for a Group Sequential Trial with Biomarker Subpopulations

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

BOIN: a Novel Bayesian Design Platform to Accelerate Early Phase Brain Tumor Clinical Trials